|
LARS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.49777976080168E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.38933350671778E-13 |
| Normal-vs-Stage2 |
1.172300E-02 |
| Normal-vs-Stage3 |
8.67894645040224E-12 |
| Normal-vs-Stage4 |
2.55450105512978E-11 |
| Stage1-vs-Stage2 |
1.320150E-02 |
| Stage1-vs-Stage3 |
1.438240E-01 |
| Stage1-vs-Stage4 |
1.827380E-01 |
| Stage2-vs-Stage3 |
9.957700E-04 |
| Stage2-vs-Stage4 |
2.162700E-03 |
| Stage3-vs-Stage4 |
8.733800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.98285832198053E-13 |
| Normal-vs-AfricanAmerican |
1.044960E-04 |
| Normal-vs-Asian |
1.07069999533138E-08 |
| Caucasian-vs-AfricanAmerican |
4.035400E-01 |
| Caucasian-vs-Asian |
7.362600E-01 |
| AfricanAmerican-vs-Asian |
5.758200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.02210470590103E-11 |
| Normal-vs-Female |
1.12689857445503E-11 |
| Male-vs-Female |
4.408800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.54249954423358E-11 |
| Normal-vs-Age(41-60Yrs) |
5.80939740757458E-11 |
| Normal-vs-Age(61-80Yrs) |
1.81439996360666E-09 |
| Normal-vs-Age(81-100Yrs) |
1.302800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.598200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.852400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.088600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.551400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.692600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.328000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.607400E-04 |
| Classical-VS-Follicular |
4.186800E-01 |
| Classical-VS-Other |
5.869800E-01 |
| Classical-VS-Normal |
5.69739810885039E-11 |
| Tall-VS-Follicular |
4.382400E-04 |
| Tall-VS-Other |
2.700800E-01 |
| Tall-VS-Normal |
1.54299906185429E-11 |
| Follicular-VS-Other |
4.611000E-01 |
| Follicular-VS-Normal |
1.29530000003708E-06 |
| Other-VS-Normal |
2.098100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.81199999449433E-09 |
| Normal-vs-N1 |
7.71205321825619E-12 |
| N0-vs-N1 |
5.284000E-02 |
|
|
